Dysplastic gangliocytoma of the cerebellum …

Kelly G Devers MD

Developmental Malformations

Updated 08.06.2024
Released 07.28.1995
Expires For CME 08.06.2027

Dysplastic gangliocytoma of the cerebellum

Author: Kelly G Devers MD

See Contributor Disclosures

Editor: Harvey B Sarnat MS MD FRCPC

Dysplastic gangliocytoma of the cerebellum

In This Article

Quick Link

Introduction

Overview

Dysplastic gangliocytoma, or Lhermitte-Duclos disease, is a rare cerebellar lesion that is described as neoplastic by some and hamartomatous by others (57). It is comprised of abnormally enlarged cells primarily in the granule cell layer. It can be associated with Cowden disease, another hamartomatous or neoplastic syndrome. Molecular studies reveal a number of dysplastic gangliocytomas to be associated with germline mutations of the PTEN gene. The author discusses the hamartomatous nature of this entity and recent molecular findings.

Key points

	• Lhermitte-Duclos is a rare, slow growing cerebellar mass composed of dysplastic ganglion cells.
	• Treatment is generally surgical, if clinically indicated; recurrences are not uncommon.
	• With MRI, the lesion has a distinctive striated pattern of hyperintensity on T-2 weighted images.
	• Lhermitte-Duclos disease is one of the major criteria for the clinical diagnosis of Cowden disease.

Historical note and terminology

The first description of a novel disorder of the cerebellum, characterized by enlarged folia with abnormal ganglion cells, was made by J. Lhermitte and P. Duclos in 1920. They referred to it as a cerebellar neurinoma, a tumor of ganglion cells arising in a congenital malformation of the cerebellum (44). The eponym bears their names: "Lhermitte-Duclos disease." The first six cases of Lhermitte-Duclos disease were described from autopsy specimens, and the first surgically removed specimen was taken in 1937 (20).

The perplexing and not well understood pathogenesis of this lesion is reflected in the many names given to it over the years: "ganglioneuroma," "dysplastic gangliocytoma," "Purkinjeoma," "hamartoma of the cerebellum," "granule cell hypertrophy," “granulomolecular hypertrophy of the cerebellum,” and "Lhermitte-Duclos disease." According to the 2016 World Health Organization Classification of Tumors of the Central Nervous System, the currently preferred name for this disease is either “dysplastic cerebellar gangliocytoma” or “Lhermitte-Duclos disease.”

Most cases reported in the literature have called the lesion a neoplasm, malformation, or dysplastic hamartoma. After Lhermitte and Duclos' description, Duncan and Snodgrass were the first to attribute the lesion of hypertrophy of the granule cells to dysplasia (17). The question of this lesion being either a neoplasm or dysplastic hamartoma has been addressed repeatedly (29). The overwhelming view is that Lhermitte-Duclos disease is a dysplastic hamartoma or malformation (82). Although few authors claim this lesion to be neoplastic, many authors have commented on its growth potential. For the sake of clarification, this author uses the term "Lhermitte-Duclos disease" and considers the entity to be dysplastic in nature, and she avoids the use of terms that may indicate neoplasia. However, if this lesion is considered neoplastic by the treating clinician, it corresponds to a WHO Grade I lesion within the “neuronal and mixed neuronal-glial tumors” category (19).

Ambler noted, as had previous authors, other malformations in patients with the cerebellar lesion and considered the disorder a probable phacomatosis like tuberous sclerosis or Von Hippel-Lindau disease (05). She also reported the first familial case of the disorder (a mother and son). Multiple reports associating Lhermitte-Duclos disease and Cowden disease (multiple hamartoma-neoplasia syndrome) have appeared in the literature since 1991 (59).

Clinical manifestations

Presentation and course

The lesion manifests itself as a slow-growing, space-occupying lesion of the cerebellum. Patients most frequently come to clinical attention with signs of increased intracranial pressure: headache, nausea, vomiting, papilledema, or visual disturbances. These symptoms occur in 75% of the cases. Cerebellar signs, such as instability in walking, cranial nerve deficits, and pyramidal signs, are less frequently observed (30% of cases) (52). Megalencephaly and seizures are often present (18). Some cases have included psychiatric symptoms, neck stiffness, orthostatic hypotension, and mental impairment. The duration of symptoms has been reported as from several months to years, with the mean being 46 months (82; 66).

Prognosis and complications

Postoperative prognosis is not easy to assess and has not been tallied in all cases of Lhermitte-Duclos disease. However, Vinchon and colleagues summarized outcomes of reported cases using 1978 as a dividing line (possibly due to advances in imaging and neurosurgery) (82). Of patients diagnosed before 1978, 10 were alive and 23 were dead in contrast to five dead and 23 living patients diagnosed since 1978. No outcome was reported in the other cases. Two patients who had Cowden disease died of metastatic carcinoma.

Recurrence has been reported in at least eight cases, often years following surgical resection (67; 83).

Data suggest genetic screening and testing for PTEN mutations for Cowden syndrome in patients with Lhermitte-Duclos disease (01; 35; 83). Studies suggest childhood-onset Lhermitte-Duclos disease is rarely associated with PTEN mutations (58).

Mutation of PTEN has been documented to be present in 80% of people with cancer susceptibility syndromes, such as Cowden syndrome (86).

In a systematic review of 302 reported cases of Lhermitte-Duclos disease, Alanazi and colleagues reported a mortality rate of 4.3% and a recurrence rate of 8.6% (03).

Clinical vignette

Case 1. A 45-year-old man was without significant medical history until, within a space of three weeks, he developed shortness of breath when jogging two miles. He began having difficulty with his balance and noted leg stiffness. He also began having headaches and increased pressure at the back of his head on bending over. A head CT revealed hydrocephalus and a mass occupying 75% of the left cerebellar hemisphere. The mass was variably dense but did not enhance. A shunt was placed for the hydrocephalus, and he underwent resection of the mass, where Lhermitte-Duclos disease was diagnosed histologically.

Case 2. A 32-year-old man with a reported history of Bannayan-Riley-Ruvalcaba syndrome, intestinal polyposis, and lower extremity arteriovenous malformation had recently complained of dizziness, headaches, and vomiting for several weeks. He did not seek medical attention. He was found deceased in his home, lying in bed. Autopsy revealed a 6’8” man with a body mass index of 31.7 kg/m². No skin lesions were present. No trauma was identified. The brain weighed 2200 grams and was markedly edematous, with cerebellar tonsillar herniation. Arising from the left cerebellar hemisphere was a well-circumscribed 8 x 7 x 5 cm mass comprised of pale tan, enlarged folia with a folded ribbon appearance. This mass compressed the fourth ventricle, and the lateral and third ventricles were markedly dilated. Additional findings included multiple lipomatous masses in both adrenal glands, nodular hyperplasia of the thyroid gland, and hyperplasia of the pituitary gland. Histopathologic study of the cerebellar lesion confirmed dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease).

Superior view of whole brain

Severe cerebral edema with markedly enlarged left cerebellar hemisphere in a 32-year-old man with headache, dizziness, and vomiting. The brain weighed 2200 grams. (Contributed by Dr. Kelly Devers.)
Cerebellar lesion, gross photo

Well-circumscribed mass arising from cerebellum with pale tan hypertrophic folia. (Contributed by Dr. Kelly Devers.)
Adrenal gland lesions, gross photo

Well-circumscribed lipomatous masses were seen in both adrenal glands. (Contributed by Dr. Kelly Devers.)
Cerebellar lesion, photomicrograph

Dysplastic ganglion cell-like neurons with prominent nucleoli and vacuolated neuropil within the granular and molecular cell layers of the cerebellar lesion. Immunohistochemical staining of this material was consistent with Lhe...

Biological basis

Etiology and pathogenesis

The etiology of Lhermitte-Duclos disease is unknown. According to a systematic review, approximately 33% of the cases of this lesion have been seen in patients with probable or definitive Cowden disease (03). Cowden disease, also known as multiple hamartoma-neoplasia syndrome, is an autosomal dominant trait. One study localized Cowden disease to chromosome 10q22-23 (55). Four of 12 families studied have members with Lhermitte-Duclos disease. The PTEN gene, containing a germline mutation, has been identified (69). It is hypothesized that the activation of rapamycin (mTOR), which is a downstream effector in the PI3K (phosphatidylinositol 3-kinase) pathway, is affected by the PTEN mutations. The product of the PTEN gene is a dual specificity phosphatase that regulates signal transduction. PTEN mutations are associated with a high rate of vascular malformations. Hypervascularization is also a reported feature of gangliocytomas (01). Of Lhermitte-Duclos disease patients, 75% to 80% appear to have a germline inactivation of PTEN (88).

The pathology of the lesion is well described (05; 27; 20; 24), and is summarized by Gessaga:

	(1) Diffuse or focal sites of cerebellar cortical hypertrophy are found involving either or both hemispheres and sometimes the vermis as well.
	(2) There is conspicuous diminution of central white matter in the involved hemisphere.
	(3) The molecular layer grossly exhibits pallor, is of increased thickness and contains myelinated nerve fibers.
	(4) A zone of abnormal nerve cells replaces the normal Purkinje and granule cell layers and sends axons into the overlaying molecular layer.
	(5) Calcareous deposits are frequently present, generally in the molecular layer, and usually are associated with small blood vessels" (27).

Cerebellar cortical hypertrophy (photomicrograph)

The lesion of the cerebellar cortex at low magnification shows enlarged, vacuolated molecular layer and hypertrophic cells replacing the Purkinje and granule cell layers. This architecture gives the lesion the gross appearance, bo...
Central white matter diminution (photomicrograph)

The central white matter of the folia is greatly reduced and the molecular layer is thickened. There are an increased number of small nuclei in the molecular layer that suggest oligodendrocytes. Myelin is stained blue. (Luxol fast...
Molecular layer hypermyelination (photomicrograph)

High magnification of the molecular layer shows hypermyelination with thick fibers coursing parallel to the pial surface of the folium. (Luxol fast blue/periodic acid-Schiff reaction; x400) (Contributed by Dr. Laura Hair.)
Normal cell layer replacement (photomicrograph)

The normal architecture of the cerebellar cortex has been replaced by hypertrophic neurons not typical of either normal Purkinje or normal granule cells. (Hematoxylin-eosin; x100) (Contributed by Dr. Laura Hair.)
Abnormal neurons (photomicrograph)

At high magnification, abnormal neurons of large and intermediate size are demonstrated, but normal cerebellar cortical neurons are not definitely identified. (Hematoxylin-eosin; x200) (Contributed by Dr. Laura Hair.)
Abnormal hypertrophic neuron characteristics (photomicrograph)

Some of the abnormal hypertrophic neurons resemble large motor neurons; others appear as enlarged teardrop-shaped ganglion cells. A few cells approaching normal granule cell morphology are encountered. (Hematoxylin-eosin; x400) (C...

Several electron microscopic examinations have shown clear and dense-core vesicles, synapses, and axon hillocks identifying cells as neuronal (64; 22; 07). These studies verify the microscopic conclusion.

Immunohistochemical studies have been conducted by Shiurba, Yachnis, and Hair (75; 85; 28). Shiurba's panel of antibodies had no specific antibodies for granule cells but did record positivity for some of the dysplastic cells with Purkinje cell features (Leu-4-a pan T-cell marker that decorates Purkinje cells), phosphorylated and nonphosphorylated neurofilament, tubulin, microtubule-associated protein, Tau, and antibodies to synaptic vesicle protein. These data would support the conclusion that the lesion is a complex hamartoma with both granule and Purkinje cell involvement. Strong acridine orange-RNA fluorescence is more similar to that of Purkinje cells than of granule cells, which show minimal RNA fluorescence (73).

RNA fluorescence in a dysplastic gangliocytoma (photomicrograph)

The enlarged neurons in a dysplastic gangliocytoma of a 16-year-old boy show moderately strong RNA fluorescence more characteristic of normal Purkinje cells than of granule cells, which normally display minimal RNA fluorescence. N...

Yachnis and colleagues believe that all the immunoreactivity of the neurofilament epitopes were consistent with hypertrophic granule cells, suggesting an abnormality of cytoskeletal regulation in these cells (85). Hair and colleagues showed positive reactivity for neurofilament but also a smaller number of dysplastic cells staining with antibodies that were specific for Purkinje cells, L 7, PEP 19 (both Purkinje cell-associated proteins, and calbindin, a calcium-binding protein found in Purkinje cells) (28). These results have been partially repeated by Ferrer and colleagues (23).

Neurofilament protein (photomicrograph)

Immunocytochemical staining for neurofilament protein in an abnormal hypertrophic cell shows an increase, probably reflecting an increased metabolism of this neuron-specific protein. (x1250) (Contributed by Dr. Laura Hair.)
Purkinje cell lineage (photomicrograph)

Immunocytochemical stain using monoclonal antibodies against calcium-binding protein of Purkinje cells (Pep-19) demonstrates reactivity in a few cells, indicating at least partial differentiation of the Purkinje cell lineage. (x20...

These studies suggest that, although hypertrophy of the granule cells is present, another population of cells with Purkinje cell features is also affected in the Lhermitte-Duclos lesion, supporting a complex hamartoma. Perhaps it reflects organization of parallel fibers or synapse formation interaction in the two cell populations (11).

Other reported pathologic findings. Tau-positive neurofibrillary tangles and neuritic threads were identified in heterotopic cerebral gray matter in a 46-year-old patient with Lhermitte-Duclos disease (72). No neurofibrillary tangles or senile plaques were found in other areas of the CNS. Capillary telangiectasias were seen in the white matter of both the cerebral and cerebellar hemispheres.

Studies of the proliferation potential of the lesion are few. Abel and colleagues demonstrated no significant proliferative activity using immunohistochemical markers in 31 cases of Lhermitte-Duclos disease (01). Their findings, including concurrent neuronal studies involving the Pten knockout mouse model, support the concept that expansion of the cerebellar mass is more likely due to cell hypertrophy rather than cell hyperplasia. Hair and colleagues showed no proliferation in their case with proliferating cell nuclear antigen and a diploid DNA index by cell image analyzer (28). In vitro labeling studies of nervous system tumors presented by Meyer and colleagues contained one case of Lhermitte-Duclos disease that revealed no proliferative activity with five foot-bromodeoxyuridine (51). One case reported by Beuche had mitotic figures (07). Immunohistochemical detection of p53 has been negative (42).

Nothing is known of the actual time sequence in evolution of the disease. Although most patients present in adulthood, some cases in teenagers, children, and newborns have been described (71; 15; 70).

There is no known animal model of the disease, though it has been recorded in a 4-year-old horse and a 2.5-year-old cat (61; 33).

Cases of enlarged cerebelli without the same histologic features have been reported (09). These cases would argue for a diffuse abnormal response of the entire cerebellum to growth factors, as opposed to a malformative lesion of one cellular type as in Lhermitte-Duclos disease.

Colby and colleagues reported a case of a 43-year-old woman who suffered a middle cerebral artery infarct and had an incidental radiologic finding consistent with Lhermitte-Duclos disease (14). She had a strong family history of colon cancer. Genetic testing revealed a germline heterozygous EGFR mutation.

Differential diagnosis

Confusing conditions

The symptoms of increased intracranial pressure and possibly cerebellar signs would force the differential diagnosis of this lesion to include any cerebellar lesion or neoplasm that would include these signs. Because the age range for Lhermitte-Duclos disease is wide, the differential includes many neoplasms and conditions. The distinctive appearance of Lhermitte-Duclos disease on MRI frequently precludes the need for biopsy; however, medulloblastoma, venous sinus thrombosis, cerebellar pleomorphic xanthoastrocytoma, anaplastic ganglioglioma, Rosai-Dorfman granuloma, cerebellar glioblastoma, pseudotumor hemicerebellitis, cerebellar-based arachnoid vascular malformation, Lhermitte-Duclos disease associated with dysembryoplastic neuroepithelial tumor (DNET), metastatic lung cancer, and subacute posterior inferior cerebellar artery stroke are reported mimics (77; 78; 36; 53; 54; 37; 74; 32; 10; 40; 49; 38).

Associated or underlying disorders

In 1991, Padberg and colleagues described an association between Cowden disease and Lhermitte-Duclos disease (59). Multiple subsequent reports regarding this association have since been published (68; 82; 79). Cowden disease, sporadically described in the literature since the 1940s, was reported as a familial disease by Lloyd and Dennis in 1963 (45). This disease is usually defined by the following dermatologic criteria: the finding of skin and mucous membrane hamartomas including facial papules, oral papillomatosis, and acral and palmoplantar keratoses. It is usually found with internal organ hamartomas or neoplasms, most frequently involving the thyroid, breast, female genitourinary tract, gastrointestinal tract, nervous system, and eye.

Of the 72 cases of Lhermitte-Duclos disease reviewed by Vinchon and colleagues, seven had definitive Cowden disease, and 26 had symptoms suggesting Cowden disease, including megalencephaly, neuronal heterotopia, leontiasis ossea, polydactyly, multiple hemangiomas, and hydromyelia (82). These data suggest both a sporadic form of Lhermitte-Duclos disease and another disease variant associated with Cowden disease. Lu and colleagues describe a case of a 16-year-old boy with diagnosed with bilateral dysplastic gangliocytoma and concurrent polyostotic fibrous dysplasia (34). Two cases of asymptomatic spinal cervical arteriovenous fistula have been reported (04). Adult-onset Lhermitte-Duclos disease is now considered a variant of Cowden syndrome and is one of the major pathognomonic diagnostic criteria for Cowden syndrome established by the International Cowden Consortium (08).

The association between Lhermitte-Duclos disease and Cowden disease was reported by Padberg and colleagues, suggesting that the combination of these may represent a new phakomatosis (59). As of 2014, approximately 53 cases of Cowden disease associated with Lhermitte-Duclos disease had been described in the literature (84). A familial case described by Ambler included a mother and son with no clinical evidence of Cowden disease (05).

Lhermitte-Duclos disease is considered a part of the PTEN hamartoma tumor syndrome, along with Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and autism spectrum disorders associated with macrocephaly (60). COLD syndrome (Concurrent Diagnosis of Cowden Syndrome and Lhermitte-Duclos Disease) is an acronym that has started appearing in the literature in the last few years.

Bannayan-Riley Ruvalcaba syndrome is a rare genetic disorder that predominantly involves mutations or deletions of the PTEN gene and is inherited in an autosomal dominant fashion. It is associated with macrocephaly, multiple hamartomatous tumors, lipomas, angiolipomas, hemangiomas, multinodular goiter, genital pigmentation in males, hypotonia, seizures, and skeletal abnormalities. This syndrome is considered part of the spectrum of the PTEN hamartoma syndrome, which also includes Cowden syndrome.

Diagnostic workup

The definitive diagnosis of Lhermitte-Duclos disease has not been made without gross or microscopic examination of tissue, but the advent of good visual resolution with magnetic resonance imaging allows presurgical consideration of this lesion. Before the advent of MRI, this disorder had not been diagnosed preoperatively. MRI and ¹H MR spectroscopy studies have shown this imaging technique to be useful in suggesting Lhermitte-Duclos disease (81; 50; 43; 26; 13; 21). Meltzer and colleagues have demonstrated that Lhermitte-Duclos disease typically presents as a nonenhancing mass of the cerebellar hemisphere with a distinctive striated pattern of hyperintensity on T-2 weighted images, echoing the enlarged folia seen grossly (50).

Dysplastic gangliocytoma (T1-weighted MRI)

This mass involves the cerebellar vermis and most of the right cerebellar hemisphere. The striated appearance is evident (yellow arrow). (Contributed by Dr. Sherman Stein.)

In contrast, other cerebellar masses such as medulloblastoma, astrocytoma, ependymoma, and hemangioblastoma destroy and obliterate the folial pattern. They also show enhancement with contrast material. An infarct of the cerebellum would manifest itself as a nonenhancing mass, but the sudden clinical presentation would not be consistent with Lhermitte-Duclos disease.

Skull x-rays may reveal an enlarged head, and the mass would appear on CT with little detail, except possibly serpigination (43).

Dysplastic gangliocytoma (CT)

Unenhanced CT scan showing a hypointense noncalcified mass in the left cerebellar hemisphere without surrounding edema. (Contributed by Dr. Laura Hair.)
Cerebellar lesion in dysplastic gangliocytoma (CT)

A hypointense noncalcified mass in the left cerebellar hemisphere without edema. The cerebellar lesion is enhanced by the intravenous administration of contrast material. (Contributed by Dr. Laura Hair.)

There are no biochemical tests for this disorder.

Of note, Ma and colleagues have reported that the characteristic striated, or “tiger stripe” appearance on T-2 weighted MRI sequences may be absent in some histopathologically confirmed pediatric cases (46). An MRI study of 14 patients with Lhermitte-Duclos disease demonstrated enhancement in 64.9%; 50% had small enhancing veins at the periphery of the lesion and an elevated apparent diffusion coefficient was noted (16).

Alanazi and colleagues reported the “tiger stripe” appearance was only present in 58.7% of 302 confirmed Lhermitte-Duclos disease cases included in their systematic review (03).

A radiologically focused case review of 21 patients with Lhermitte-Duclos disease revealed the typical “tiger stripe” appearance was more common in patients with Lhermitte-Duclos disease who had other tumors (30). Patients without other tumors were more likely to have intratumoral calcification, abnormal blood vessels, intratumoral hemorrhage, peritumoral edema, and heterogeneous enhancement.

One manuscript has described that the MRI finding of a low cholinesterase/noradrenaline (Cho/NAA) ratio and the appearance of a lactate peak (Lac), in conjunction with the “tiger-striped” sign can aid in diagnostic accuracy of Lhermitte-Duclos disease (41).

Management

Treatment of this disease is generally surgical. Extent of resection has been difficult to determine because the gyral pattern is preserved and there is no clear distinction between affected and non-affected tissue. MRI imaging techniques facilitate better surgical planning of resection margins for these lesions (50). In more diffuse lesions, consideration should be given to suboccipital decompression, CSF shunting, or both (43).

One case of Lhermitte-Duclos has been reported with medical management (76). The increased intracranial pressure caused by the mass was treated with anti-edema drugs, but the outcome of this case is unknown. Abi Lahoud and colleagues advocate medical management, leaving surgical excision for intractable increased intracranial pressure (02). Mittal and colleagues recommend obtaining diffusion-weighted imaging sequences and possibly MR spectroscopy to differentiate from medulloblastoma, an aggressive malignant tumor, or other mimics (53; 37). Praharaj and colleagues report a case of venous sinus thrombosis causing radiologic diagnostic confusion with Lhermitte-Duclos disease (62).

In 2017, Zak and colleagues reported a case of an infant with severe bilateral hydrocephalus and radiologically diagnosed Lhermitte-Duclos disease, whose symptoms resolved with rapamycin therapy (87). A 50-year-old Cowden syndrome patient with bilateral recurrent dysplastic gangliocytomas was initially treated with resection of the larger lesion, followed by recurrence of the resected lesion and progression of the unresected lesion. The patient was subsequently treated with temozolomide, which appeared to slow progression, followed by second resection of the contralateral lesion 8 years after the first resection (39).

Outcomes

Before the advent of surgical intervention, approximately 33% of patients with this disease died due to increased intracranial pressure as the neoplasm grew within the posterior cranial fossa. In 1937, in a literature review by Erna Christensen, a case of successful surgical excision was described, with the patient reportedly “living and well, one and one-half years after extensive removal of the abnormal cerebellar cortex” (12; 17).

In a systematic review of 302 reported cases of Lhermitte-Duclos disease in PubMed, Alanazi reported a mortality rate of 4.3% and a recurrence rate of 8.6% (03).

Today, surgical intervention resulting in relief of symptoms predominantly results in increased long-term survival and relief of symptoms. However, Prestor reports a case of severe postoperative cerebellar syndrome in a patient requiring extensive resection (63). Afshar-Oromieh reported two cases with postoperative cerebellar mutism (06).

Wang and colleagues published a study of 12 patients with histopathologically confirmed Lhermitte-Duclos disease who were treated from 2004 to 2017 (83). Ages ranged from 3 to 55 years with a mean follow-up of 89.1 +/- 36.9 months. All patients underwent surgical resection, most of which were subtotal or partial resections. One patient experienced recurrence. Cowden syndrome was diagnosed in four of these patients.

Also, in 2017, Jiang and colleagues published a study of 18 patients, 17 of which had histopathologically confirmed Lhermitte-Duclos disease who were treated from 2001 to 2017 (35). These patients ranged in age from 2 to 61 years. Seventeen of these patients underwent surgical resection. Determining tumor margins was considered the most challenging part of the surgical procedure. Follow-up ranged from 6 to 180 months (mean of 52 months), and it revealed one case of treated subdural hematoma, one case of death due to diabetes mellitus two years after resection, and one case of fatal intracranial glioma two years after resection. Eleven of these patients were diagnosed with Cowden syndrome.

Historically, cases treated with radiation therapy have either resulted in a few years of symptom relief or a decline in neurologic functioning (31; 47). Histopathological study of tumors that have been irradiated or treated with gamma knife have developed vascular proliferation (35). Spontaneous intratumoral hemorrhage has been reported in untreated cases as well (46; 80).

Media

References

01: Abel T, Baker S, Fraser M, et al. Lhermitte-Duclos Disease: A report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol 2005;64:341-9. PMID 15835270
02: Abi Lahoud G, Chalouhi N, Zanaty M, Rizk T, Jabbour P. Association of Lhermitte-Duclos disease and split cord malformation in a child. J Clin Neurosci 2014;21(11);1999-2002. PMID 24938384
03: Alanazi A, Alanezi T, Aljofan Z, Alarabi A, Elwatidy S. Lhermitte-Duclos disease: a systematic review. Surg Neurol Int 2023;14:351. PMID 37810307
04: Almubarak AO, Haq A, Alzahrani I, Shail E. Lhermitte-Duclos disease with cervical arteriovenous fistula. J Neurol Surg A Cent Eur Neurosurg 2019;80(2):134-7. PMID 30517962
05: Ambler M, Pogacar S, Sidman R. Lhermitte-Duclos disease (granule cell hypertrophy of the cerebellum). Pathological analysis of the first familial cases. J Neuropathol Exp Neurol 1969;28:622-47. PMID 5345120
06: Afshar-Oromieh A, Linhart H, Podlesek D, Schrempf W, Schackert G, Krex D. Postoperative cerebellar mutism in adult patients with Lhermitte-Duclos disease. Neurosurg Rev 2010;33(4):401-8. PMID 20668902
07: Beuche W, Wickboldt J, Freide RL. Lhermitte-Duclos disease--its minimal lesions in electron microscope data and CT findings. Clin Neuropathol 1983;2:163-70. PMID 6652989
08: Blumenthal G, Dennis P. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008;16(11):1289-300. PMID 18781191
09: Bodensteiner JB, Schaefer GB, Keller GM, Thompson JM, Bowen MK. Macrocerebellum: neuroimaging and clinical features of a newly recognized condition. J Child Neurol 1997;12(6):365-8. PMID 9309519
10: Bosemani T, Steinlin M, Toelle SP, et al. Pseudotumoral hemicerebellitis as a mimicker of Lhermitte -Duclos disease in children: does neuroimaging help to differentiate them? Childs Nerv Syst 2016;32(5):865-71. PMID 26649682
11: Burgoyne RD, Cambray-Deakin MA. The cellular neurobiology of neuronal development: the cerebellar granule cell. Brain Res 1988;472(1):77-101. PMID 3277691
12: Christensen E. Über Ganglienzellgeschwülste im Gehirn. Virchows Archive für pathologische Anatomie und Physiologie und für klinische Medizin 1937;Oct 300:567.
13: Cianfoni A, WIntermark M, Piludu F, et al. Morphological and functional MR imaging of Lhermitte-Duclos disease with pathology correlate. J Neuroradiol 2008;35(5):297-300. PMID 18692898
14: Colby S, Yehia L, Niazi F, et al. Exome sequencing reveals germline gain-of-function EGFR mutation in an adult with Lhermitte-Duclos disease. Cold Spring Harb Mol Case Stud 2016;2(6):a001230 PMID 27900366
15: Deitlein M, Schroder R, Widemann B, Benz-Bohm G. Dysplastic gangliocytoma of cerebellum in a newborn. Diagnosis by ultrasonography and MRI. Pediatr Radiol 1992;22:131-3. PMID 1501942
16: Dhamija R, Wood C, Porter A, et al. Updated imaging features of dysplastic cerebellar gangliocytoma. J Comput Assist Tomogr 2019;43(2):277-81. PMID 30407243
17: Duncan D, Snodgrass SR. Diffuse hypertrophy of the cerebellar cortex (myelinated neurocytoma). Arch Neurol Psychiatry 1943;50:677-84.
18: Eberhart CG, Weistler OD, Eng C. Cowden disease and dysplastic gangliocytoma of the cerebellum/Lhermitte-Duclos disease. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO Classification of Tumors of the Central Nervous System. 4th ed. Lyon: IARC, 2007:226-228.
19: Eberhart CG, Weistler OD, Eng C. Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease). In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO Classification of Tumors of the Central Nervous System. Rev 4th ed. Lyon: IARC, 2016:142-6.
20: Faillot T, Sichez JP, Brault JL, et al. Lhermitte-Duclos disease (dysplastic gangliocytoma of the cerebellum). Report of a case and review of the literature. Acta Neurochir 1990;105:44-9. PMID 2239379
21: Fauria-Robinson C, Meyers R, Castillo-Jorge S, Nguyen J, Palacios E. Dysplastic cerebellar gangliocytoma Lhermitte-Duclos disease imaging and magnetic resonance spectroscopy. J La State Med Soc 2014;166(5):193-6. PMID 25369219
22: Ferrer I, Isamat F, Acebes J. A Golgi and electron microscopic study of a dysplastic gangliocytoma of the cerebellum. Acta Neuropathol (Berl) 1979;47:163-5. PMID 474077
23: Ferrer I, Isamat F, Lopez-Obarrio l, et al. Paralbumin and calbindin D-28K immunoreactivity in central ganglioglioma and dysplastic gangliocytoma of the cerebellum. Report of 2 cases. J Neurosurg 1993;78:133-7. PMID 8416231
24: Ferrer L, Marti E, Guionnet N, et al. Studies with the Golgi method in central gangliogliomas and dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease). Histol Histopathol 1990;5:329-36. PMID 1724930
25: Franko A, Hojar-Erlic I, Miletic D, Petrovic O. Lhermitte-Duclos disease and pregnancy. Radiol Oncol 2006;40(1):17-21.
26: Gaballo A, Palma M, Dicuonzo F, Carell A. Lhermitte-Duclos disease: MR diffusion and spectroscopy. Radiol Med 2005;110(4):378-84. PMID 16292245
27: Gessaga EC. Lhermitte Duclos disease (diffuse hypertrophy of the cerebellum). Report of 2 cases. Neurosurg Rev 1980;3:151-8. PMID 7231686
28: Hair LS, Symmans F, Powers JM, Carmel P. Immunohistochemistry and proliferative activity in Lhermitte-Duclos disease. Acta Neuropathol (Berl) 1992;84:570-3. PMID 1462769
29: Hallervorden J. Uber die Hamartome (ganglioneurome) des Kleinhirns. Dtsch Z Nervenheilkd 1959;179:531-63. PMID 14399105
30: Han C, Xhang Y, Ran C, Luo Y, Li W. Diverse imaging findings of Lhermitte-Duclos disease. Clin Radiol 2023;78(1):33-9. PMID 36182334
31: Heitkamp JW, Rose JE. Neck pain following migration of a ventriculocervical shunt. Surg Neurol 1983;19(3):285-7. PMID 6340229
32: Huang S, Zhang G, Zhang J. Similar MR imaging characteristics but different pathological changes: a misdiagnosis for Lhermitte-Duclos disease and review of the literature. Int J Clin Exp Pathol 2015;8(6):7583-7587. PMID 26261673
33: Imlau M, Mamoun S, Cryan J, et al. Dysplastic gangliocytoma of the cerebellum in a cat. Vet Pathol 2022;59(3):459-62. PMID 35130805
34: Jiang C, Lu WX, Yan GZ, et al. Bilateral dysplastic gangliocytoma with concurrent polyostotic fibrous dysplasia: a case report and literature review. World Neurosurg 2020;141:421-4. PMID 32561490
35: Jiang T, Wang J, Du J, et al. Lhermitte-Duclos disease and cerebellar gangliocytoma and Cowden syndrome: clinical experience from a single institution with long-term follow-up. World Neurosurg 2017;104:398-406. PMID 28479525
36: Johnston JM, Limbrick DD, Ray WZ, Brown S, Shimony J, Park TS. Isolated cerebellar Rosai-Dorfman granuloma mimicking Lhermitte-Duclos disease: Case report. J Nuerosurg Pediatr 2009;4(2):118-120. PMID 19645543
37: Kamble RB, Mathew S, Rao RM. Infiltrating medulloblastoma in a child mimicking Lhermitte-Duclos disease. J Pediatr Neurosci 2012;7(2):159-60. PMID 23248708
38: Kesim S, Ozguven S, Oksuzoglu K, Erdil T. Lhermitte-Duclos disease related with Cowden syndrome mimicking metastatic lung cancer on FDG PET/CT. Clin Nucl Med 2023;48:c99-100. PMID 36607384
39: Khandpur U, Huntoon K, Smith-Cohn M, Shaw A, Elder JB. Bilateral recurrent dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease) in Cowden syndrome: a case report and review of the literature. World Neurosurg 2019;127:319-25. PMID 30905649
40: Kikuchi K, Hiratsuka Y, Kohno S, Ohue S, Miki H, Mochizuki T. Radiological features of cerebellar glioblastoma. J Neuroradiol 2016;43(4):260-5. PMID 26740386
41: Kohle A, Shenoy A, Tayal S, Goel N. Lhermitte-Duclos disease: a series of six cases. J Neurosci Rural Pract 2023;14(1):127-31. PMID 36891111
42: Kuchelmeister K, Elborg B, Gullotta F. Immunohistochemical detection of P53 protein in tumors of the central nervous system. Pathologica 1995;87(5):498-502. PMID 8868174
43: Kulkantrakorn K, Awwad EE, Levy B, et al. MRI in Lhermitte-Duclos disease. Neurology 1997;48:725-31. PMID 9065555
44: Lhermitte J, Duclos P. Sur un ganglioneurome diffus du cortex du cervelet. Bull Assoc Fr Etud Cancer 1920;9:99-107.
45: Lloyd KM, Dennis M. Cowden's disease. Ann Intern Med 1963;58:136-42. PMID 13931122
46: Ma J, Jia G, Chen S, Jia W. Clinical perspective on dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease). World Neurosurg 2018;122:16-23. PMID 30366139
47: Marano SR, Johnson PC, Spetzler RF. Recurrent Lhermitte-Duclos disease in a child. Case report. J Neurosurg 1988;69(4):599-603. PMID 3418394
48: Matsumoto H, Minami H, Yoshida Y. Lhermitte-Duclos disease treated surgically in an elderly patient: case report and literature review. Turk Neurosurg 2015;25(5):783-7. PMID 26442547
49: Mehkri Y, Poe J, Nasrullah I, et al. Subacute posterior inferior cerebellar artery stroke radiographically mimicking Lhermitte-Duclos disease. Cureus 2022;14(11):331381. PMID 36514563
50: Meltzer CC, Smirniotopoulos JG, Jones RV. The striated cerebellum: an MR imaging sign in Lhermitte-Duclos disease (dysplastic gangliocytoma). Radiology 1995;194:699-703. PMID 7862965
51: Meyer JS, Marchisky JA, Hickey WF. Cell kinetic classification of tumors of the nervous system by DNA precursor labeling in vitro. Hum Pathol 1993;24:1357-64. PMID 8276384
52: Milbouw G, Born JD, Martin D, et al. Clinical and radiological aspects of dysplastic gangliocytoma (Lhermitte Duclos disease): a report of 2 cases with review of the literature. Neurosurgery 1988;22:124-8. PMID 3278250
53: Mittal P, Gupta K, Saggar K, Kaur S. Adult medulloblastoma mimicking Lhermitte-Duclos disease: can diffusion weighted imaging help. Neurol India 2009;57(2):203-5. PMID 19439857
54: Nair P, Pal L, Jaiswal AK, Behari S. Lhermitte-Duclos disease associated with dysembryoplastic neuroepithelial tumor differentiation with characteristic magnetic resonance imaging of tiger striping. World Neurosurg 2011;75:699-703. PMID 21704939
55: Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996;13:114-6. PMID 8673088
56: Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et al. Cancer risk and genotpe-phenotype correlations in PTEN hamartoma tumor syndrome. Fam Cancer 2014;13(1):57-63. PMID 23934601
57: Nowak DA, Trost HA. Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma): a malformation, hamartoma, or neoplasm? Acta Neurol Scand 2002;105(3):137-45. PMID 11886354
58: Okamoto K, Natsumeda M, Oishi M, Fujii Y. Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease). No Shinkei Geka 2021;49(2):395-9. PMID 33762463
59: Padberg GW, Schot JD, Vielvoye GJ, Bots GT, de Beer FC. Lhermitte-Duclos disease and Cowden disease; a single phakomatosis. Ann Neurol 1991;29:517-23. PMID 1859181
60: Pilarski R. PTEN hamartoma tumor syndrome: a clinical overview. Cancers (Basel) 2019;11(6):844. PMID 31216739
61: Poss M, Young S. Dysplastic disease of the cerebellum of an adult horse. Acta Neuropathol (Berl) 1987;75:209-11. PMID 3434227
62: Praharaj HN, Singh MK, Garg RK, Raut TP. Intracranial venous sinus thrombosis mimicking Lhermitte Duclos disease. BMJ Case Rep 2012;2012. PMID 23148398
63: Prestor B. Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease). J Clin Neurosci 2006;13(8):877-81. PMID 169344474
64: Pritchett PS, King TI. Dysplastic gangliocytoma of the cerebellum--an ultrastructural study. Acta Neuropathol 1978;42:1-5. PMID 207069
65: Puiseux C, Bretonnier M, Proisy M, Chappe C, Denizeau P, Riffaud L. Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease) presenting as a prenatally heterotopic hamartoma. Childs Nerv Syst 2020. PMID 32621005
66: Rainov NG, Holzhausen HJ, Burkert W. Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease). Clin Neurol Neurosurg 1995;97:175-80. PMID 7656495
67: Reeder RF, Saunders RL, Roberts DW, Fratkin JD, Cromwell LD. Magnetic resonance imaging in the diagnosis and treatment of Lhermitte-Duclos disease (dysplastic gangliocytoma of the cerebellum). Neurosurgery 1988;23:240-5. PMID 3185886
68: Rimbau J, Isamat F. Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease) and its relation to the multiple hamartoma syndrome (Cowden disease). J Neurooncol 1994;18(3):191-7. PMID 7964980
69: Robinson S, Cohen AR. Cowden disease and Lhermitte-Duclos disease: characterization of a new phakomatosis. Neurosurg 2000;46:371-83. PMID 10690726
70: Robinson S, Cohen AR. Cowden disease and Lhermitte-Duclos disease: an update. Case report and review of the literature. Neurosurg Focus 2006;20(1):E1-6. PMID 16459996
71: Roessmann U, Wongmongkolrit T. Dysplastic gangliocytoma of cerebellum in a newborn. J Neurosurg 1984;60:845-7. PMID 6707754
72: Rusiecki D, Lach B. Lhermitte-Duclos disease with neurofibrillary tangles in heterotopic cerebral gray matter. Folia Neuropathol 2016:54(2):190-6. PMID 27543776
73: Sarnat HB. Repartition de l'ARN au cours de la migration neuronale dans les cerveaux normaux et dysplastiques en developpement chez l'homme; etude a l'acridine-orange. Rev Neurol (Paris) 1989;145(2):127-33. PMID 2471246
74: Sarvardekar A, Salunke P, Ahuja CK, Rane S, Singla N. Unusual presentation in adult medulloblastomas: imaging features mimicking cerebellar dysplastic gangliocytoma (Lhermitte-Duclos disease). Neurol India 2012;60(5):555-7. PMID 23135053
75: Shiurba RA, Gessaga EC, Eng LF, Sternberger LA, Sternberger NH, Urich H. Lhermitte-Duclos disease. An immunohistochemical study of the cerebellar cortex. Acta Neuropathol 1988;75:474-80. PMID 3287833
76: Sonier CB, Feve JR, deKersaint-Gilly A, Ruchoux MM, Rymer R, Auffray E. Lhermitte-Duclos disease: a rare case of intracranial hypertension in adults. J Neuroradiol 1992;19:133-8. PMID 1629776
77: Takei H, Dauser R, Su J, et al. Anaplastic ganglioglioma arising from a Lhermitte-Duclos-like lesion. Case report. J Neurosurg 2007;107(2 Suppl):137-42. PMID 18459885
78: Takei H, Rouah E, Battacharjee M. Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1: a case report and literature review. Int J Clin Exp Pathol 2015;8(6):7570-4. PMID 26261671
79: Tan TC, Ho LC. Lhermitte-Duclos disease with Cowden syndrome. J Clin Neurosci 2007;14(8):801-5. PMID 17485210
80: Uchida D, Nakatogawa H, Inenaga C, Tanaka T. An unusual case of Lhermitte-Duclos disease manifesting with intratumoral hemorrhage. World Neurosurg 2018;114:326-9. PMID 29625313
81: Verheggen R, Bruhn H, Schroder BU, Frahm J, Markakis E. Lhermitte-Duclos disease: a critical appraisal of different radiologic methods. Eur J Radiol 1994;19(1):21-4. PMID 7859755
82: Vinchon M, Blond S, Lejeune JP, et al. Association of Lhermitte-Duclos and Cowden disease: report of a new case and review of the literature. J Neurol Neurosurg Psychiatry 1994;57:699-704. PMID 8006650
83: Wang Q, Zhang S, Hui X, et al. Lhermitte-Duclos disease: clinical study with long-term follow-up in a single institution. Clin Neurol Neurosurg 2017;162:53-8. PMID 28938107
84: Wei G, Zhang W, Li Q, et al. Magnetic resonance characteristics of adult-onset Lhermitte-Duclos disease: an indicator for active cancer surveillance. Mol Clin Oncol 2014;2(3):415-420. PMID 24772310
85: Yachnis AT, Trojanowski JQ, Memmo M, Schlaepfer WW. Expression of neurofilament proteins in the hypertrophic granule cells of Lhermitte-Duclos disease: an explanation for the mass effect and the myelination of parallel fibers in the disease state. J Neuropathol Exp Neurol 1988;47:206-16. PMID 3130464
86: Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene 2008;27(41):5443-53. PMID 18794879
87: Zak M, Ledbetter M, Maertens P. Infantile Lhermitte-Duclos disease treated successfully with rapamycin. J Child Neurol 2017;32(3):322-6. PMID 27932596
88: Zhou XP, Marsh DJ, Morrison CD, et al. Germline Inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte Duclos disease in adults. Am J Hum Genet 2003;73(5):1191-8. PMID 14566704

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Kelly G Devers MD

Dr. Devers of the University of South Florida and Deputy Chief Medical Examiner for Hillsborough County has no relevant financial relationships to disclose.
See Profile

Editor

Harvey B Sarnat MS MD FRCPC

Dr. Sarnat of the University of Calgary has no relevant financial relationships to disclose.
See Profile

Former Authors

Laura S Hair MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: Female:male
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Malignant neoplasm of cerebellum: C71.6

Benign neoplasm of brain: D33.1

Neoplasm of uncertain behavior of brain and spinal cord: D43.1
ICD-11: Mixed neuronal-glial tumors: 2A00.21

Primary neoplasm of brain of unknown or unspecified type: 2A00.5

Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos): XH6K00
ICD-O-3: Dysplastic gangliocytoma of cerebellum: 9493/0
OMIM: Cowden syndrome 1; CSS1, Lhermitte-Duclos disease, included: 158350

Phosphatase and tensin homolog; PTEN: 601728

PTEN hamartoma tumor syndrome; PHTS: 158350

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Dysplastic gangliocytoma of the cerebellum

Associated Disorders

Bannayan-Riley-Ruvalcaba syndrome
COLD syndrome
Cowden disease
Cowden syndrome
PTEN hamartoma tumor syndrome

Differential Diagnosis

cerebellar lesion
cerebellar neoplasm
medulloblastoma
venous sinus thrombosis
cerebellar pleomorphic xanthoastrocytoma
- anaplastic ganglioglioma
- Rosai-Dorfman granuloma
- cerebellar glioblastoma
- pseudotumor hemicerebellitis
- cerebellar-based arachnoid malformations

Dysplastic gangliocytoma of the cerebellum

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

X-linked hydrocephalus (L1 syndrome)

Cerebro-oculo-facio-skeletal syndrome

Schizencephaly

Fetal anticonvulsant syndrome

Rhombencephalosynapsis

Malformations of the brain

Von Hippel-Lindau disease

Vein of Galen malformations

This is an article preview.
Start a Free Account
to access the full version.